Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H.

Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496.

PMID:
29997251
2.

Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried-Blood Spot Samples.

Lamoury FMJ, Hajarizadeh B, Soker A, Martinez D, Quek C, Cunningham P, Catlett B, Cloherty G, Marks P, Amin J, Grebely J, Dore GJ, Applegate TL.

J Mol Diagn. 2018 Jun 26. pii: S1525-1578(17)30296-9. doi: 10.1016/j.jmoldx.2018.05.010. [Epub ahead of print]

PMID:
29959023
3.

Elimination of Hepatitis C Virus in Australia: Laying the Foundation.

Dore GJ, Hajarizadeh B.

Infect Dis Clin North Am. 2018 Jun;32(2):269-279. doi: 10.1016/j.idc.2018.02.006. Review.

PMID:
29778255
4.

Management of acute HCV infection in the era of direct-acting antiviral therapy.

Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV.

Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):412-424. doi: 10.1038/s41575-018-0026-5. Review.

PMID:
29773899
5.

Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012.

Alavi M, Grebely J, Hajarizadeh B, Amin J, Larney S, Law MG, George J, Degenhardt L, Dore GJ.

BMC Infect Dis. 2018 May 9;18(1):215. doi: 10.1186/s12879-018-3110-0.

6.

Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay.

Lamoury FMJ, Bajis S, Hajarizadeh B, Marshall AD, Martinello M, Ivanova E, Catlett B, Mowat Y, Marks P, Amin J, Smith J, Ezard N, Cock V, Hayllar J, Persing DH, Kleman M, Cunningham P, Dore GJ, Applegate TL, Grebely J; LiveRLife Study Group.

J Infect Dis. 2018 May 25;217(12):1889-1896. doi: 10.1093/infdis/jiy114.

PMID:
29534185
7.

Observations on the launch of new drugs for hepatitis C.

Martinello M, Hajarizadeh B, Dore GJ.

Aust Prescr. 2018 Feb;41(1):4-5. doi: 10.18773/austprescr.2018.005. Epub 2018 Feb 1. No abstract available.

8.

Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014).

Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, Matthews GV, Law M, Dore GJ.

Hepatol Commun. 2017 Aug 16;1(8):736-747. doi: 10.1002/hep4.1073. eCollection 2017 Oct.

9.

Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study.

Cunningham EB, Hajarizadeh B, Amin J, Bretana N, Dore GJ, Degenhardt L, Larney S, Luciani F, Lloyd AR, Grebely J; HITS-p Investigators.

Int J Drug Policy. 2018 Apr;54:18-25. doi: 10.1016/j.drugpo.2017.12.013. Epub 2018 Jan 24.

PMID:
29367011
10.

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.

Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.

PMID:
29310928
11.

Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.

Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ.

J Viral Hepat. 2018 Jun;25(6):640-648. doi: 10.1111/jvh.12852. Epub 2018 Feb 19.

PMID:
29274192
12.

Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study.

Alavi M, Janjua NZ, Chong M, Grebely J, Aspinall EJ, Innes H, Valerio H, Hajarizadeh B, Hayes PC, Krajden M, Amin J, Law MG, George J, Goldberg DJ, Hutchinson SJ, Dore GJ.

J Viral Hepat. 2018 May;25(5):473-481. doi: 10.1111/jvh.12837. Epub 2018 Feb 6.

PMID:
29194861
13.

The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.

Alavi M, Janjua NZ, Chong M, Grebely J, Aspinall EJ, Innes H, Valerio HM, Hajarizadeh B, Hayes PC, Krajden M, Amin J, Law MG, George J, Goldberg DJ, Hutchinson SJ, Dore GJ.

J Hepatol. 2018 Mar;68(3):393-401. doi: 10.1016/j.jhep.2017.10.019. Epub 2017 Oct 26.

PMID:
29107152
14.

The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative.

Esmaeili A, Mirzazadeh A, Morris MD, Hajarizadeh B, Sacks HS, Maher L, Grebely J, Kim AY, Lauer G, Cox AL, Hellard M, Dietze P, Bruneau J, Shoukry NH, Dore GJ, Lloyd AR, Prins M, Page K; InC3 Collaborative.

Clin Infect Dis. 2018 Jan 6;66(1):20-28. doi: 10.1093/cid/cix768.

PMID:
29020200
15.

Addressing cultural diversity: the hepatitis B clinical specialist perspective.

Wallace J, Smith E, Hajarizadeh B, Richmond J, Lucke J.

Ethn Health. 2017 Aug 31:1-13. doi: 10.1080/13557858.2017.1370540. [Epub ahead of print]

PMID:
28854823
16.

HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype.

Shepherd SJ, McDonald SA, Palmateer NE, Gunson RN, Aitken C, Dore GJ, Goldberg DJ, Applegate TL, Lloyd AR, Hajarizadeh B, Grebely J, Hutchinson SJ.

J Med Virol. 2018 Jan;90(1):120-130. doi: 10.1002/jmv.24919. Epub 2017 Sep 18.

PMID:
28843002
17.

Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Grebely J, Hajarizadeh B, Dore GJ.

Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):641-651. doi: 10.1038/nrgastro.2017.106. Epub 2017 Aug 23. Review.

PMID:
28831184
18.

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ.

J Hepatol. 2017 Dec;67(6):1204-1212. doi: 10.1016/j.jhep.2017.07.025. Epub 2017 Aug 9.

PMID:
28802876
19.

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review.

Bajis S, Dore GJ, Hajarizadeh B, Cunningham EB, Maher L, Grebely J.

Int J Drug Policy. 2017 Sep;47:34-46. doi: 10.1016/j.drugpo.2017.07.002. Epub 2017 Aug 7. Review.

PMID:
28797498
20.

More than a virus: a qualitative study of the social implications of hepatitis B infection in China.

Wallace J, Pitts M, Liu C, Lin V, Hajarizadeh B, Richmond J, Locarnini S.

Int J Equity Health. 2017 Aug 1;16(1):137. doi: 10.1186/s12939-017-0637-4.

21.

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.

Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop A, Foster GR, Hellard M, Robaeys G, Thurnheer MC, Weltman M, Amin J, Marks PS, Quiene S, Dore GJ, Dalgard O, Grebely J; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:230-238. doi: 10.1016/j.drugpo.2017.05.040. Epub 2017 Jun 19.

PMID:
28633998
22.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group.

Int J Drug Policy. 2017 Sep;47:177-186. doi: 10.1016/j.drugpo.2017.05.020. Epub 2017 Jun 16.

PMID:
28624134
23.

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.

Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group.

BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3.

24.

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.

Lamoury FMJ, Soker A, Martinez D, Hajarizadeh B, Cunningham EB, Cunningham P, Bruggmann P, Foster GR, Dalgard O, Backmund M, Conway B, Robaeys G, Swan T, Cloherty G, Marks P, Grebely J, Dore GJ, Applegate TL.

J Clin Virol. 2017 Jul;92:32-38. doi: 10.1016/j.jcv.2017.05.007. Epub 2017 May 11.

25.

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study.

Grebely J, Lamoury FMJ, Hajarizadeh B, Mowat Y, Marshall AD, Bajis S, Marks P, Amin J, Smith J, Edwards M, Gorton C, Ezard N, Persing D, Kleman M, Cunningham P, Catlett B, Dore GJ, Applegate TL; LiveRLife Study Group.

Lancet Gastroenterol Hepatol. 2017 Jul;2(7):514-520. doi: 10.1016/S2468-1253(17)30075-4. Epub 2017 Apr 22.

PMID:
28442271
26.

HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.

Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV.

Curr HIV/AIDS Rep. 2017 Jun;14(3):110-121. doi: 10.1007/s11904-017-0358-8. Review.

PMID:
28432579
27.

Hepatitis C treatment as prevention: evidence, feasibility, and challenges.

Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ.

Lancet Gastroenterol Hepatol. 2016 Dec;1(4):317-327. doi: 10.1016/S2468-1253(16)30075-9. Epub 2016 Nov 10. Review.

PMID:
28404202
28.

Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.

Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, Luciani F, Teutsch S, Dolan K, Lloyd AR, Grebely J; HITS-p investigators.

J Viral Hepat. 2017 Sep;24(9):733-741. doi: 10.1111/jvh.12701. Epub 2017 Apr 10.

PMID:
28256027
29.

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline.

Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H, Nikbin M, Nabavi M, Adibi P, Ziaee M, Behnava B, Rezaee-Zavareh MS, Colombo M, Massoumi H, Bizri AR, Eghtesad B, Amiri M, Namvar A, Hesamizadeh K, Malekzadeh R.

Hepat Mon. 2016 Aug 13;16(8):e40959. eCollection 2016 Aug. Review.

30.

Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.

Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili A, Hajarizadeh B, Sacks HS, Page KA.

J Viral Hepat. 2017 Feb;24(2):117-127. doi: 10.1111/jvh.12628. Epub 2016 Oct 28. Review.

31.

Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study.

Alavi M, Law MG, Grebely J, Amin J, Hajarizadeh B, George J, Dore GJ.

J Hepatol. 2016 Nov;65(5):879-887. doi: 10.1016/j.jhep.2016.06.025. Epub 2016 Jul 8.

PMID:
27401548
32.

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden.

Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H.

Hepat Mon. 2016 Jun 14;16(7):e37234. doi: 10.5812/hepatmon.37234. eCollection 2016 Jul.

33.

Hepatitis B-Related Concerns and Anxieties Among People With Chronic Hepatitis B in Australia.

Hajarizadeh B, Richmond J, Ngo N, Lucke J, Wallace J.

Hepat Mon. 2016 May 21;16(6):e35566. doi: 10.5812/hepatmon.35566. eCollection 2016 Jun.

34.

Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).

Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, Matthews GV, Law M, Dore GJ.

J Hepatol. 2016 Dec;65(6):1086-1093. doi: 10.1016/j.jhep.2016.08.010. Epub 2016 Aug 26.

PMID:
27569777
35.

HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection.

Lamoury FM, Hajarizadeh B, Keoshkerian E, Feld JJ, Amin J, Teutsch S, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Applegate TL, Grebely J; ATAHC Study Group.

BMC Infect Dis. 2016 Jun 1;16:241. doi: 10.1186/s12879-016-1567-2.

36.

Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection.

Sheridan DA, Hajarizadeh B, Fenwick FI, Matthews GV, Applegate T, Douglas M, Neely D, Askew B, Dore GJ, Lloyd AR, George J, Bassendine MF, Grebely J.

Liver Int. 2016 Dec;36(12):1774-1782. doi: 10.1111/liv.13176. Epub 2016 Jul 5.

PMID:
27224844
37.

Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment.

Hajarizadeh B, Grebely J, McManus H, Estes C, Razavi H, Gray RT, Alavi M, Amin J, McGregor S, Sievert W, Thompson A, Dore GJ.

J Gastroenterol Hepatol. 2017 Jan;32(1):229-236. doi: 10.1111/jgh.13453.

PMID:
27197716
38.

Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection.

Hajarizadeh B, Lamoury FM, Feld JJ, Amin J, Keoshkerian E, Matthews GV, Hellard M, Dore GJ, Lloyd AR, Grebely J, Applegate TL; ATAHC Study Group.

Virol J. 2016 Feb 24;13:32. doi: 10.1186/s12985-016-0482-x.

39.

HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.

Bartlett SR, Jacka B, Bull RA, Luciani F, Matthews GV, Lamoury FM, Hellard ME, Hajarizadeh B, Teutsch S, White B, Maher L, Dore GJ, Lloyd AR, Grebely J, Applegate TL.

Infect Genet Evol. 2016 Jan;37:252-8. doi: 10.1016/j.meegid.2015.11.028. Epub 2015 Nov 26.

40.

Strategies to manage hepatitis C virus infection disease burden - volume 3.

Alfaleh FZ, Nugrahini N, Matičič M, Tolmane I, Alzaabi M, Hajarizadeh B, Valantinas J, Kim DY, Hunyady B, Abaalkhail F, Abbas Z, Abdou A, Abourached A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla MA, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alashgar HI, Alavian SM, Alawadhi S, Al-Dabal L, Aldins P, Alghamdi AS, Al-Hakeem R, Aljumah AA, Almessabi A, Alqutub AN, Alswat KA, Altraif I, Andrea N, Assiri AM, Babatin MA, Baqir A, Barakat MT, Bergmann OM, Bizri AR, Chaudhry A, Choi MS, Diab T, Djauzi S, El Hassan ES, El Khoury S, Estes C, Fakhry S, Farooqi JI, Fridjonsdottir H, Gani RA, Ghafoor Khan A, Gheorghe L, Goldis A, Gottfredsson M, Gregorcic S, Gunter J, Hamid S, Han KH, Hasan I, Hashim A, Horvath G, Husni R, Jafri W, Jeruma A, Jonasson JG, Karlsdottir B, Kim YS, Koutoubi Z, Lesmana LA, Liakina V, Lim YS, Löve A, Maimets M, Makara M, Malekzadeh R, Memon MS, Merat S, Mokhbat JE, Mourad FH, Muljono DH, Nawaz A, Olafsson S, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Salupere R, Sanai FM, Sanityoso Sulaiman A, Sayegh RA, Schmelzer JD, Sharara AI, Sibley A, Siddiq M, Siddiqui AM, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan MA, Taha M, Tanaka J, Tarifi H, Tayyab G, Ud Din M, Umar M, Videčnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf MA, Zuberi BF, Blach S.

J Viral Hepat. 2015 Dec;22 Suppl 4:42-65. doi: 10.1111/jvh.12474.

PMID:
26513447
41.

The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, Salupere R, Assiri AM, Goldis A, Abaalkhail F, Abbas Z, Abdou A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla MA, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alavian SM, Alashgar HI, Alawadhi S, Al-Dabal L, Aldins P, Alfaleh FZ, Alghamdi AS, Al-Hakeem R, Aljumah AA, Almessabi A, Alqutub AN, Alswat KA, Altraif I, Alzaabi M, Andrea N, Babatin MA, Baqir A, Barakat MT, Bergmann OM, Bizri AR, Blach S, Chaudhry A, Choi MS, Diab T, Djauzi S, El Hassan ES, El Khoury S, Estes C, Fakhry S, Farooqi JI, Fridjonsdottir H, Gani RA, Ghafoor Khan A, Gheorghe L, Gottfredsson M, Gregorcic S, Gunter J, Hajarizadeh B, Hamid S, Hasan I, Hashim A, Horvath G, Hunyady B, Husni R, Jeruma A, Jonasson JG, Karlsdottir B, Kim DY, Kim YS, Koutoubi Z, Liakina V, Lim YS, Löve A, Maimets M, Malekzadeh R, Matičič M, Memon MS, Merat S, Mokhbat JE, Mourad FH, Muljono DH, Nawaz A, Nugrahini N, Olafsson S, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Sanai FM, Sanityoso Sulaiman A, Sayegh RA, Sharara AI, Siddiq M, Siddiqui AM, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan MA, Taha M, Tanaka J, Tarifi H, Tayyab G, Tolmane I, Ud Din M, Umar M, Valantinas J, Videčnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf MA, Zuberi BF, Schmelzer JD.

J Viral Hepat. 2015 Dec;22 Suppl 4:21-41. doi: 10.1111/jvh.12476.

PMID:
26513446
42.

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.

Liakina V, Hamid S, Tanaka J, Olafsson S, Sharara AI, Alavian SM, Gheorghe L, El Hassan ES, Abaalkhail F, Abbas Z, Abdou A, Abourached A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla MA, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alashgar HI, Alawadhi S, Al-Dabal L, Aldins P, Alfaleh FZ, Alghamdi AS, Al-Hakeem R, Aljumah AA, Almessabi A, Alqutub AN, Alswat KA, Altraif I, Alzaabi M, Andrea N, Assiri AM, Babatin MA, Baqir A, Barakat MT, Bergmann OM, Bizri AR, Blach S, Chaudhry A, Choi MS, Diab T, Djauzi S, El Khoury S, Estes C, Fakhry S, Farooqi JI, Fridjonsdottir H, Gani RA, Ghafoor Khan A, Goldis A, Gottfredsson M, Gregorcic S, Hajarizadeh B, Han KH, Hasan I, Hashim A, Horvath G, Hunyady B, Husni R, Jafri W, Jeruma A, Jonasson JG, Karlsdottir B, Kim DY, Kim YS, Koutoubi Z, Lesmana LA, Lim YS, Löve A, Maimets M, Makara M, Malekzadeh R, Matičič M, Memon MS, Merat S, Mokhbat JE, Mourad FH, Muljono DH, Nawaz A, Nugrahini N, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Salupere R, Sanai FM, Sanityoso Sulaiman A, Sayegh RA, Schmelzer JD, Sibley A, Siddiq M, Siddiqui AM, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan MA, Taha M, Tarifi H, Tayyab G, Tolmane I, Ud Din M, Umar M, Valantinas J, Videčnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf MA, Zuberi BF, Gunter J.

J Viral Hepat. 2015 Dec;22 Suppl 4:4-20. doi: 10.1111/jvh.12475.

PMID:
26513445
43.

Patients' perspectives on the delivery of hepatitis B management and care.

Richmond J, Hajarizadeh B, Wallace J.

Aust Fam Physician. 2015 Jun;44(6):346. No abstract available.

PMID:
26427092
44.

Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.

Lamoury FM, Bartlett S, Jacka B, Hajarizadeh B, Grebely J, Matthews GV, Dore GJ, Applegate TL.

J Mol Diagn. 2015 Sep;17(5):583-9. doi: 10.1016/j.jmoldx.2015.05.003. Epub 2015 Jul 4.

45.

Hepatitis B knowledge and associated factors among people with chronic hepatitis B.

Hajarizadeh B, Wallace J, Richmond J, Ngo N, Enright C.

Aust N Z J Public Health. 2015 Dec;39(6):563-8. doi: 10.1111/1753-6405.12378. Epub 2015 Jun 11.

PMID:
26095536
46.

Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, Spelman T, Bruneau J, Prins M, Kim AY, McGovern BH, Shoukry NH, Schinkel J, Allen TM, Morris M, Hajarizadeh B, Maher L, Lloyd AR, Page K, Hellard M; InC3 study group.

J Infect Dis. 2015 Nov 1;212(9):1407-19. doi: 10.1093/infdis/jiv220. Epub 2015 Apr 15.

47.

Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Dore GJ, Grebely J; InC3 Study Group.

PLoS One. 2015 Apr 2;10(4):e0122232. doi: 10.1371/journal.pone.0122232. eCollection 2015.

48.

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC3 Study Group.

J Viral Hepat. 2015 Sep;22(9):708-17. doi: 10.1111/jvh.12384. Epub 2015 Jan 8.

49.

Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study.

Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J; InC(3)Study Group.

J Clin Virol. 2014 Nov;61(3):430-4. doi: 10.1016/j.jcv.2014.08.027. Epub 2014 Sep 8.

50.

Dynamics of HCV RNA levels during acute hepatitis C virus infection.

Hajarizadeh B, Grebely J, Applegate T, Matthews GV, Amin J, Petoumenos K, Hellard M, Rawlinson W, Lloyd A, Kaldor J, Dore GJ; ATAHC study group.

J Med Virol. 2014 Oct;86(10):1722-9. doi: 10.1002/jmv.24010. Epub 2014 Jul 8.

Supplemental Content

Loading ...
Support Center